QSAR models using a large diverse set of estrogens

被引:318
作者
Shi, LM
Fang, H
Tong, WD [1 ]
Wu, J
Perkins, R
Blair, RM
Branham, WS
Dial, SL
Moland, CI
Sheehan, DM
机构
[1] ROW Sci Inc, Jefferson, AR 72079 USA
[2] Natl Ctr Toxicol Res, Div Genet & Reprod Toxicol, Jefferson, AR 72079 USA
来源
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES | 2001年 / 41卷 / 01期
关键词
D O I
10.1021/ci000066d
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Endocrine disruptors (EDs) have a variety of adverse effects in humans and animals. About 58 000 chemicals, most having little safety data, must be tested in a group of tiered assays. As assays will take years, it is important to develop rapid methods to help in priority setting. For application to large data sets, we have developed an integrated system that contains sequential four phases to predict the ability of chemicals to bind to the estrogen receptor (ER), a prevalent mechanism for estrogenic EDs. Here we report the results of evaluating two types of QSAR models for inclusion in phase III to quantitatively predict chemical binding to the ER. Our data set for the relative binding affinities (RBAs) to the ER consists of 130 chemicals covering a wide range of structural diversity and a 6 orders of magnitude spread of RBAs. CoMFA and HQSAR models were constructed and compared for performance. The CoMFA model had a r(2) = 0.91 and a q(LOO)(2) = 0.66. HQSAR showed reduced performance compared to CoMFA with r(2) = 0.76 and q(LOO)(2) = 0.59. A number of parameters were examined to improve the CoMFA model. Of these, a phenol indicator increased the q(LOO)(2) to 0.71. When up to 50% of the chemicals were left out in the leave-N-out cross-validation, the q(2) remained significant. Finally, the models were tested by using two test sets; the q(pred)(2) for these were 0.71 and 0.62, a significant result which demonstrates the utility of the CoMFA model for predicting the RBAs of chemicals not included in the training set. If used in conjunction with phases I and II, which reduced the size of the data set dramatically by eliminating most inactive chemicals, the current CoMFA model (phase III) can be used to predict the RBA of chemicals with sufficient accuracy and to provide quantitative information for priority setting.
引用
收藏
页码:186 / 195
页数:10
相关论文
共 37 条
  • [11] CROSS-VALIDATION, BOOTSTRAPPING, AND PARTIAL LEAST-SQUARES COMPARED WITH MULTIPLE-REGRESSION IN CONVENTIONAL QSAR STUDIES
    CRAMER, RD
    BUNCE, JD
    PATTERSON, DE
    FRANK, IE
    [J]. QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1988, 7 (01): : 18 - 25
  • [12] COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS
    CRAMER, RD
    PATTERSON, DE
    BUNCE, JD
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) : 5959 - 5967
  • [13] Quantitative comparisons of in vitro assays for estrogenic activities
    Fang, H
    Tong, WD
    Perkins, R
    Soto, AM
    Prechtl, NV
    Sheehan, DM
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 2000, 108 (08) : 723 - 729
  • [14] FANG H, 2000, IN PRESS CHEM RES TO
  • [15] Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.1289/ehp.96104s4715
  • [16] Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β
    Kuiper, GGJM
    Lemmen, JG
    Carlsson, B
    Corton, JC
    Safe, SH
    van der Saag, PT
    van der Burg, P
    Gustafsson, JÄ
    [J]. ENDOCRINOLOGY, 1998, 139 (10) : 4252 - 4263
  • [17] Leo A, 1995, EXPLORING QSAR FUNDA
  • [18] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    Lipinski, CA
    Lombardo, F
    Dominy, BW
    Feeney, PJ
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) : 3 - 25
  • [19] PERKINS R, 2000, ESTROGEN KNOWLEDGE B
  • [20] Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis cross-validated r2-guided region selection approach
    Sadler, BR
    Cho, SJ
    Ishaq, KS
    Chae, K
    Korach, KS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (13) : 2261 - 2267